Altheos
South San Francisco
About Altheos
Altheos, Inc. is an early stage biopharmaceutical company based in the San Francisco Bay area focused on development of highly promising near-clinical and clinical stage novel small molecule drugs. Altheos, Inc. completed $20MM series A financing in March 2010 led by Bay City Capital with participation from Novo A/S, Canaan Partners, Life Science Angels and Atheneos Capital. The financing will be used primarily for the development of ATS907, a selective Rho-kinase inhibitor for topical treatment of glaucoma that Altheos licensed from a Japanese pharmaceutical company. The license also includes a series of highly active compounds specifically for topical treatment for glaucoma.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $32.5M
- Funding stage: Early Stage Venture
- Last round: Series A (Feb 2012)
- Website: altheos.net
- Phone: +1 650-989-8570
Industries & Categories
Biotechnology, Clinical Trials, Health Care
Canonical: https://fsome.com/organization/altheos-2101950 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.